🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Poland / NCT07117643
Enrolling by invitation Not applicable

Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies

NCT07117643 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2025-01-01
Last updated
2025-08-12

Condition(s) studied

Sport MedicineSportPhysiological AdaptationsSport PerformanceRemote Ischemic PreconditioningIschemic Preconditioning

Investigational drug(s) / intervention(s)

Ischemic Preconditioning

Ischemic Preconditioning: The ischemic procedure will be carried out before the start of the WanT and eccentric exercises procedures and muscle damage in accordance with the detailed description of the RIPC procedure. Four-fold filling of the flotation flange will be performed by 5 minutes to the value of 200 mm Hg with 5 minutes' rest interval near the attachment of the initial straight thigh muscle. All performed procedures will be carried out under the Doppler USG control to perform full arterial blood flow restriction. The whole research will be carried out in the Laboratory in morning hours. Each participant will be in a hydrated state and before the first meal.

Study summary

Both in sports and medicine, methods that can significantly contribute to improving the ability of tissues to perform their functions are constantly being searched. One of those methods that is increasingly used also in sports is remote ischemic preconditioning (RIPC). Mostly, this procedure involves repeated brief cycles of limb ischemia/reperfusion. This method is often referred as ischemic blood reperfusion and helps to increase the tolerance of treated tissues to the occurrence of possible ischemic episodes in the future. Numerous studies have shown that RIPC induces changes that lead to increased resistance to hypoxia and other stressors in organs (brain, heart, liver). In addition, it has been proven that induction of arterial occlusion in the area of selected limbs before performing physical exercises can affect the improvement of their function, and thus can translate into sports results. In addition, an adaptation of such fibres to damage is mostly associated with the secretion of many factors that influence body function. That's why we conclude that it may affect protein kinases (such like c-Jun N-terminal kinases (JNKs) or serine-threonine kinase = protein kinase B (AKTs)) whose main role is regulation of the activity of a wide spectrum of substrates, influencing cells proliferation, apoptosis, responses to cellular stress and inflammatory process in normal and cancer cells. Concluding that presented kinases activity is associated with cells differentiation and RIPC and physical activity may affect them and the inflammation process that may lead to cytotoxic activity against cancer cells (especially if the effects are combined together). The beneficial increase of anti-tumour activity of the blood serum against pathological isolated tumour cells of prostate cancer (cell lines - LNCaP and PC- 3) was confirmed in our pilot studies. We observed an increase in the anti-cancer properties of serum taken from people that attended RIPC training and performed physical activity. However, the exact mechanism and associated changes in the proteome of blood serum people attending in the RIPC training have not yet been determined. This knowledge would allow us to determine the exact mechanisms of the reperfusion/reocclusion training on the human body and its beneficial activity. Considering that the skeletal muscle is an organ capable of synthesis and release of a number of proteins, cytokines and low molecular weight compounds, especially during physical activity, it should be assumed that intermittent muscle ischemic episodes will lead to increased release of factors that will increase the resistance of muscles and other tissues to stress. At the same time, it was noticed that under conditions of muscular stress induced changes in iron metabolism occur. The binding of free iron through the ferritin protein at the cell level leads to its greater resistance to stressors. In the prism of the above considerations, the results of our preliminary studies showing that the upper limb RIPC procedures cause changes in iron metabolism in white blood cells and may suggest that the procedure of RIPC leads to changes that allow storing iron in a safe form in as ferritin. At the same time, with the increasing interest in iron metabolism, the role and function of amyloid precursor protein (APP) and hepcidin are increasing. It has been proven that APP is a protein that works with ferroportin, thus taking part in iron export from a cell. Moreover, it has been shown that the post-translational modification of APP leads to the formation of amyloid α (determines positive changes) and amyloid β (negative changes). Because there are some indications that sAPPα may be modified by iron changes and associated with cfDNA changes, which substantially increase during i.e. tissue damage, we would like to explore those correlations more deeply. The same decrease in the APP protein level will lead to the inhibition of iron export from the cell and an increase of its concentration in the cell. The nature of such changes in iron metabolism should be considered as adaptive to the ischemic stress on which muscle is exposed during the RIPC procedure. The increase in ferritin in the cell leads to a decrease in the concentration of free iron and thus a reduction in iron-dependent ROS formation. This project will have an impact on the development of the current state of knowledge of the mechanisms of biochemical response to the specific tissue-affecting method in form of remote ischemic preconditioning and will allow determining the role of sAPPα and Cathepsin C and other trophic factors and changes in iron metabolism in this process, taking into account the role of hepcidin and vitamin D. Moreover, the present project may contribute to the determination of the role of presented procedures on cells proliferation, as an example of anti-tumour proprieties, and changes of human serum proteomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
49 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Dependent on the studied population: 1. Population of not training grope age and morphologically appropriate participation will take part. Participants will be recruited basing on a voluntary letter of intent. All representatives of the analyzed group participating in the pre-qualification research will fill in the physical activity sheet - Global Health Activity Questionnaire - World Health Organization in Polish adaptation. This will allow to eliminate people who report high levels of physical activity (similar to the level of sport training individuals). 2. Aerobic sport training Population (long distance runners, marathon runners and other). Participants will be recruited basing on a voluntary letter of intent. All representatives of the analysed group participating in the pre-qualification research will fill in the physical activity sheet - Global Health Activity Questionnaire - World Health Organization in Polish adaptation. All participants have to declare minimum 5 marathon run history (similar to the level of sport results during the run). Exclusion Criteria: * taking medicines during the study, * history of cardiovascular disorders, * history of autonomic nervous system disorders, * history of mental disorders, * history of cerebro-cranial traumas, * history of other diseases that may directly affect obtained results, * concurrent injuries, * drugs intake, * supplements consumption

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Gdansk University of Physical Education and Sport Gdansk Pomeranian Voivodeship
University of Physical Education and Sport (GUPES) Gdansk Pomeranian Voivodeship

More Gdansk University of Physical Education and Sport trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07117643 on ClinicalTrials.gov ↗ ← All trials in Poland